SMS Pharmaceuticals is trading 0.88% upper at Rs 217.45 as compared to its last closing price. SMS Pharmaceuticals has been trading in the price range of 218.80 & 211.95. SMS Pharmaceuticals has given -16.40% in this year & 5.42% in the last 5 days. SMS Pharmaceuticals has TTM P/E ratio 49.91 as compared to the sector P/E of 28.67.The company posted a net profit of 14.10 Crores in its last quarter.Listed peers of SMS Pharmaceuticals include TTK Health Care (0.23%), Syncom Formulations India (-0.11%), SMS Pharmaceuticals (0.88%).The Mutual Fund holding in SMS Pharmaceuticals was at 2.55% in 31 Dec 2024. The MF holding has decreased from the last quarter. The FII holding in SMS Pharmaceuticals was at 0.31% in 31 Dec 2024. The FII holding has decreased from the last quarter.
Updated on Feb 07, 2025, 11:08 AM UTC
|
|
|
|
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
---|---|---|---|---|---|---|---|---|
TTK Health Care | Moderately Bearish | 1,299.40 | 0.23 | 1,858.36 | 29.13 | 1.83 | 0.77 | 0.08 |
Syncom Formulations India | Neutral | 18.44 | -0.11 | 1,730.41 | 63.55 | 5.87 | - | - |
SMS Pharmaceuticals | Neutral | 217.45 | 0.88 | 1,839.19 | 33.94 | 3.15 | 0.20 | 22.76 |
Hesteriosciences | Bearish | 1,870.00 | -2.14 | 1,590.78 | 89.41 | 5.54 | 0.32 | 64.12 |
Bliss Gvs Pharma | Neutral | 149.70 | -2.54 | 1,574.34 | 15.99 | 1.56 | 0.35 | 4.64 |
Meeting Date | Purpose |
---|---|
2025-02-12 | Quarterly Results |
2024-11-08 | Quarterly Results |
2024-08-05 | Quarterly Results |
2024-05-29 | Audited Results & Final Dividend |
2024-02-08 | Quarterly Results & Preferential issue |
SMS Pharmaceuticals is trading at 217.45 as on Fri Feb 07 2025 09:56:54. This is 0.88% upper as compared to its previous closing price of 215.55.
The market capitalization of SMS Pharmaceuticals is 1839.19 Cr as on Fri Feb 07 2025 09:56:54.
The 52 wk high for SMS Pharmaceuticals is 398.00 whereas the 52 wk low is 122.05
SMS Pharmaceuticals can be analyzed on the following key metrics -
SMS Pharmaceuticals reported a net profit of 49.83 Cr in 2024.